Group 1 - The company He Yuan Bio (688765.SH) plans to issue 89.451354 million shares, accounting for 25.02% of the total share capital after the issuance, without involving shareholder public offerings [1] - The strategic placement will include participation from CITIC Securities and Haitong Innovation Investment, with a maximum subscription amount of 240 million yuan for CITIC and an initial follow-on ratio of 5% for Haitong [1] - The initial inquiry date for the issuance is set for October 9, 2025, with subscription starting on October 14, 2025, followed by an application for stock listing on the Shanghai Stock Exchange [1] Group 2 - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [1] - The core product HY1001 has completed domestic Phase III clinical trials, achieving both primary and secondary endpoints with good safety results [1] - The company's net profits attributable to the parent company for the years 2022 to the first half of 2025 are projected to be -143.5763 million yuan, -186.9629 million yuan, -151.3681 million yuan, and -81.6278 million yuan respectively [1] Group 3 - If the stock issuance is successful, the raised funds (after deducting issuance costs) will be invested in the construction of a recombinant human protein industrialization base, new drug research and development projects, and to supplement working capital [2]

Group 1 - The core viewpoint of the article is that Wuhan Heyuan Biotechnology Co., Ltd. has been approved for IPO by the Shanghai Stock Exchange, marking it as the 30th company to pass this year [1] - Heyuan Biotechnology is an innovative biopharmaceutical company with a leading global plant-based bioreactor technology platform, focusing on products including pharmaceuticals, pharmaceutical excipients, and research reagents [1][2] - The company plans to issue 89.45 million shares, accounting for 25.02% of the total share capital post-issue, and aims to raise 240 million yuan for projects including the construction of a human serum albumin industrialization base and new drug research and development [2] Group 2 - The controlling shareholder and actual controller of the company is Yang Daichang, who holds 40.29 million shares, representing 15.03% of the total share capital, and indirectly controls an additional 10.05 million shares, totaling 18.78% [2] - The main questions raised during the listing committee meeting included inquiries about the advanced nature of the core technologies, market space estimation for the drug HY1001, and safety compliance measures for the production of medicinal rice [3]